CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2088
Issued: 2026-10-16

PRODUCT IDENTIFICATION

PRODUCT
Selank 10 mg

SKU / INTERNAL CODE
CRF-2026-2088

PRESENTATION
Lyophilised powder, 10 mg vial

BATCH NUMBER
LOT-2610-2088

CLIENT
veltispeptides.mx

SAMPLE RECEIVED
2026-10-11

ANALYSIS DATE
2026-10-14

PRODUCTION DATE
2026-10-09

ISSUED
2026-10-16

EXPIRY / RETEST
2028-10-16

MOLECULAR FORMULA
C33H57N11O9

MOLECULAR WEIGHT
751.9

CAS NUMBER
129954-34-3

ANALYTICAL METHOD

PANEL
SILVER - HPLC-UV + LC-MS/MS + ICP-MS (Pb/As/Cd/Hg) + LAL endotoxin

METHOD
RP-HPLC-UV 214 nm · LC-MS/MS ESI Q-TOF · ICP-MS · LAL kinetic chromogenic (USP <85>)

INSTRUMENT
Agilent 1290 · Agilent 7900 ICP-MS · Charles River Endosafe nexgen-PTS

Column: C18 2.1×100mm | Temperature: 35°C | Mobile phase: 0.1% TFA H2O / ACN | Flow: 0.4 mL/min | Retention time: 5.8 min

CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2088
Issued: 2026-10-16

1. PURITY & ASSAY - RP-HPLC-UV (214 nm)

Test	Specification	Result	Status
HPLC Purity	≥98.0%	99.4%	PASS
Quantity	95.0-105.0%	10.1 mg (101.0%)	PASS

2. LC-MS/MS STRUCTURAL CONFIRMATION

Test	Reported data	Status
Theoretical [M+H]+	752.9 | Observed: 753.0 | Δ +0.10 Da	PASS
Sequence Coverage (MS/MS)	≥95% | 100% (Thr-Lys-Pro-Arg-Pro-Gly-Pro, 7 aa)	PASS
Key fragments	b2 314.2 · b3 411.3 · b5 622.4 · y3 340.2 · y5 551.3	PASS
Modifications	free N-terminal Thr, C-terminal Pro free acid, no acetylation, no diketopiperazine	PASS

RESEARCH USE ONLY - NOT FOR HUMAN OR VETERINARY USE

3. HEAVY METALS - ICP-MS (USP <232>/<233>)

Test	Specification	Result	Status
Pb	≤5.0 µg/g	<0.05 µg/g	PASS
As	≤15.0 µg/g	<0.10 µg/g	PASS
Cd	≤2.0 µg/g	<0.02 µg/g	PASS
Hg	≤3.0 µg/g	<0.01 µg/g	PASS

4. ENDOTOXIN - LAL kinetic chromogenic (USP <85>)

Test	Reported data	Status
Result	<1.0 EU/mg limit | 0.28 EU/mg | PPC recovery 87%	PASS

FINAL BATCH RESULT

PASS - Conforms to specifications

ANALYST NOTES

Tuftsin analogue, heptapeptide. Pro2/Pro5 stabilise against exopeptidase; no degradation products above 0.2%.

crafa

CRAFA